The most recent search for references to relevant research was carried out in March 2012. No trials were found for inclusion in this systematic review.
Low-dose aspirin is frequently used as 'treatment as normal' in control groups and as a baseline treatment in pharmacological trials.
There is still no good evidence that aspirin is effective in treating patients with a diagnosis of vascular dementia.
There is increasing concern that low-dose aspirin is associated with increased risk of haemorrhages.
Further research is needed to assess the effect of aspirin on cognition, and on other outcomes such as haemorrhages, mortality, institutionalisation and behaviour.
However, the feasibility of such research is limited by a number of factors, including the widespread use of low-dose aspirin for secondary prevention of cerebrovascular and cardiovascular conditions, and its low cost and lack of patent, which limit commercial interest in investing in these studies. In addition, there is increasing evidence of its potential to cause harm from haemorrhages, especially gastric and cerebral haemorrhages that can be fatal.
P L A I N L A N G U A G E S U M M A R Y

There is no evidence that aspirin improves the symptoms of vascular dementia
Low-dose aspirin can improve the prognosis of heart disease and stroke, possibly by reducing clot formation within the blood vessels and helping to maintain or improve blood flow to the heart and brain. Many doctors assume that aspirin will also provide some benefit for people with vascular dementia.
This systematic review shows that there is no evidence to suggest that aspirin is useful for people with vascular dementia. It is possible that vascular dementia and stroke are caused by different pathological processes. Practitioners need to be aware of the risks of aspirin, such as haemorrhages, which can be fatal.
B A C K G R O U N D Description of the condition
Dementia is a syndrome consisting of a cluster of symptoms. The core feature is cognitive impairment, which may include deterioration in memory, verbal and non-verbal intellectual abilities, spatial orientation, attention, recognition and interpretation of perceptions. There may also be changes in personality, motivation, and regulation of emotions and behaviour. Each individual's symptom profile will depend on the areas of brain affected. The condition progresses and occurs in clear consciousness. Vascular dementia is a subtype of dementia and "is the result of infarction of the brain owing to vascular disease, including hypertensive cerebrovascular disease. The infarcts are usually small but cumulative in their effect. Onset is usually in later life" (ICD 10 2010). This term includes multi-infarct dementia, arteriosclerotic dementia, vascular dementia of acute onset, subcortical vascular dementia, mixed cortical and subcortical vascular dementia, leukoariosis and Binswanger's disease.
Description of the intervention
Aspirin is acetylsalicylic acid. It has analgesic, anti-pyretic, antiinflammatory and anti-platelet clumping properties. In the 5th century BC Hippocrates used the bitter powder from willow bark, which contains salicylic acid, as an anti-pyretic and analgesic. There are worldwide historical examples of its use, for instance by Native Americans, Middle Eastern civilisations and in medieval England. In 1828 the French pharmacist Leroux isolated salicylic acid, which is also found in the wild flower, meadowsweet. Hoffmann, working for Bayer, synthesised and sold aspirin as a powder and in 1899 this was patented. Eleven days later Bayer also patented the opiate heroin. In 1915 aspirin tablets were created and in 1917 the patent expired. Aspirin tablets are available worldwide but the dosages vary. For instance, in the UK it is available as 75 mg and 300 mg tablets, and 300 mg suppositories. The standard tablet in the US is 325 mg, the baby aspirin tablet is 81 mg and in Europe aspirin is available as 100 mg tablet (cardioaspirin). The recommended analgesic dose is 300 to 900 mg every four to six hours, while the recommended dose for secondary prevention of thrombotic cerebrovascular and cardiovascular disease is 75 to 300 mg daily. Low-dose aspirin is generally defined as 75 to 300 mg/day.
How the intervention might work
Aspirin causes a non-competitive, irreversible inhibition of cyclooxygenase (COX) 1, 2 and 3. Its actions vary with the dose. At low doses (75 to 300 mg/day) it irreversibly blocks COX 1, which is necessary for thromboxane A2 (TXA2) synthesis. Lowered thromboxane levels reduce platelet stickiness and reduce vasoconstriction. Hence, at low doses (300 mg/day or less) aspirin reduces the formation of intravascular clots and emboli and improves peripheral blood flow. Low-dose aspirin has little effect on prostaglandins. Although aspirin is metabolised after a few hours, platelets are unable to synthesis more COX 1 so this effect lasts several days until more platelets are manufactured. At high doses (1.2 to 3.6 g/day) aspirin acts predominantly on COX 2, which converts arachidonic acid to prostaglandins throughout the body. Thus at high doses, aspirin, like nonsteroidal anti-inflammatory drugs, reduces prostaglandin synthesis and has anti-pyrexial, anti-inflammatory and analgesic properties, and can cause gastritis. The anti-inflammatory effects are mediated by vasoconstriction. There is little effect on platelet stickiness. Thus, aspirin affects the balance between TXA2, which promotes aggregation of platelets and local vasoconstriction, and prostacyclin (PGI2), which inhibits aggregation. At low doses, aspirin decreases TXA2 synthesis without significantly reducing PGI2 synthesis, thus reducing platelet aggregation and promoting local vasodilation. By this mechanism or others, low-dose aspirin can improve outcomes for patients after a stroke or myocardial infarction. Aspirin is widely prescribed for the management of stroke and myocardial infarction with a view to preventing further episodes. APT 1994 found that long-term anti-platelet treatment given to people who have suffered transient ischaemic attacks or mild ischaemic strokes reduced the proportional risk of non-fatal stroke by one third and fatal stroke by one fifth. It was also suggested that although there is some evidence that aspirin increases risk of intracranial haemorrhage, the overall stroke rate is still reduced. Many clinicians assume that aspirin may benefit patients with vascular dementia by similar mechanisms and it is widely prescribed for these patients (Dennis 1998). In one study of practice by geriatricians and psychiatrists in the UK, more than 80% of patients with cognitive impairment and vascular risk factors were prescribed aspirin. In one survey of Canadian specialists in subcortical vascular dementia (Molnar 1998), 86% of respondents prescribed aspirin. A retrospective case note analysis of patients with vascular dementia showed a statistically insignificant trend towards both increased life expectancy and time to institutionalisation in those regularly taking low-dose aspirin (Devine 2003). Aspirin has complex pharmacological actions that could affect the progress of dementias. If the aetiology of dementia is ischaemic, as proposed in vascular dementia, the pharmacological effects of low-dose aspirin predict a beneficial effect on symptoms and prognosis. If the aetiology of any dementia is inflammatory then the mechanisms of aspirin treatment suggest that high-dose aspirin may be beneficial and improve prognosis. However, the pharmacological effects of aspirin also predict a possible worsening of symptoms. It is possible that aspirin causes small cerebral haemorrhages that could stimulate the amyloid cascade, a theoretical model for Alzheimer's disease. There is increasing concern that aspirin is linked to cerebral haemorrhages that may be primary or secondary. Again these are predicted by its known actions on platelets and small blood vessels. It is well known that aspirin can cause gastric haemorrhages, probably via its anti-prostaglandin actions, and that these can be fatal. As aspirin has a range of pharmacological effects it is possible that it will be found to influence the progress of different dementias in different ways, either beneficially or adversely.
Why it is important to do this review
It is important to do this review to determine whether aspirin improves cognition or prognosis for patients with vascular dementia. This is important because it is a widely prescribed drug and has the potential risk of haemorrhage.
O B J E C T I V E S
To assess the randomised trial evidence for efficacy and safety of aspirin in the treatment of vascular dementia.
It primarily aims to assess cognitive, behavioural and global outcomes.
The secondary objective is to assess the effect of the aspirin on mortality, morbidity and institutionalisation.
M E T H O D S Criteria for considering studies for this review
Types of studies
Randomised controlled trials of aspirin for the treatment of vascular dementia are eligible for inclusion.
Types of participants
Participants of any age with a diagnosis of vascular dementia, as defined in the description of the condition (i.e. this term includes multi-infarct dementia, arteriosclerotic dementia, vascular dementia of acute onset, subcortical vascular dementia, mixed cortical and subcortical vascular dementia, leukoariosis and Binswanger's disease).
Types of interventions
Trials assessing the effect of aspirin versus control (placebo or no placebo), with a minimum of six months' follow-up, were considered for inclusion, regardless of dosage.
Types of outcome measures
Primary outcomes of interest were:
• cognition, using validated scales;
• behaviour, using validated scales;
• global function.
Secondary outcomes were:
• institutionalisation;
• morbidity, for example, gastric and cerebral haemorrhage;
• mortality. To view a list of all sources searched for ALOIS see About ALOIS on the ALOIS website. Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the 'methods used in reviews' section within the editorial information about the Dementia and Cognitive Improvement Group. Additional searches were performed in many of the sources listed above to cover the timeframe from the last searches performed for ALOIS to ensure that the search for the review was as up-to-date and as comprehensive as possible. The search strategies used can be seen in Appendix 1. The latest searches of July 2011 and March 2012, retrieved a total of 267 and 57 results respectively. After a first-assess and a deduplication of these results the authors were left with 35 and 10 references from each search to assess further. In addition, relevant websites and journals were searched for trials.
Search methods for identification of studies
Searching other resources
Specialists in the field were approached for unpublished material and any publications found were searched for additional references.
Data collection and analysis
Selection of trials
Two review authors (GR, MO) independently considered the studies identified by the search against the inclusion criteria.
Data extraction
As there were no studies suitable for inclusion in this systematic review, data were not formally extracted.
R E S U L T S Description of studies
See: Characteristics of excluded studies. There were no studies eligible for the review.
Risk of bias in included studies
There were no included studies.
Effects of interventions
There were no studies eligible to be included, as updated in March 2012.
D I S C U S S I O N
Low-dose aspirin has been widely prescribed for patients with a diagnosis of vascular dementia for many years. It is often assumed that because it has confirmed benefit in stroke, it will have benefit in vascular dementia. However, there is some evidence that the pathogenesis of these two conditions may differ. Furthermore, aspirin is often considered a safe treatment although evidence is accruing that it has significant risks of haemorrhage. Therefore both the advantages and disadvantages of prescribing low-dose aspirin for patients with vascular dementia must be considered.
There were no eligible studies that could be included in this review. The Meyer 1989 study was excluded on detailed inspection of its methodology. We had wished to assess cognitive, behavioural and global outcomes in addition to mortality, morbidity (specifically haemorrhages) and institutionalisation data, but this was not possible.
There are difficulties in assessing the effect of aspirin in vascular dementia. Vascular dementia is often diagnosed with reference to a history of stroke or myocardial infarction and such patients are likely to be taking aspirin already. This presents difficulty in constructing a placebo-controlled trial.
A U T H O R S ' C O N C L U S I O N S Implications for practice
This review alerts the physician to the fact that despite the widespread prescription of aspirin in patients with vascular dementia, there is no empirical evidence to support this practice.
Implications for research
There is a case to be made for a multicentre randomised doubleblind placebo-controlled trial assessing the effect of aspirin on cognition. In addition, the behavioural and global domains need to be assessed. Mortality, morbidity and institutionalisation data should also be measured.
However, the risk of potentially fatal haemorrhage associated with low-dose aspirin may make such a study unethical.
It would also be useful to research the mechanism underlying the effects of aspirin on the neurobiological bases of cognition, for instance blood flow studies, neuroimaging and detailed neuropsychological testing.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of excluded studies [ordered by study ID]
Study
Reason for exclusion
AD 2000
This was a randomised open-label trial of low-dose aspirin in 310 community-resident patients with probable Alzheimer's dementia and was part of a trial of donepezil. There were no significant benefits in terms of cognition or functional abilities but the risk of haemorrhage was significantly greater in the treatment group (risk ratio 4. 4; 95% confidence interval 1.5 to 12.8; P = 0.007)
ASPREE 2008
A history of dementia was 1 of the key exclusion criteria in this protocol
Broe 2000
This was a community survey, not a treatment study 50 drugs or drug groups were categorised and their use by people with Alzheimer's and vascular dementias analysed (Continued) S10 S5 or S6 or S7 or S8 or S9 S11 S4 and S10 S12 EM 2008 S13 EM 2009 S14 EM 2010 S15 EM 2011 S16 S12 or S13 or S14 or S15 S17 S11 and S16 
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